InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,705.65
(
-0.23%
)
US TECH 100
19,267.60
(
-0.28%
)
Dow Jones
42,146.03
(
0.05%
)
Brent Oil
74.50
(
1.04%
)
Bitcoin
62,940.50
(
-0.61%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 228

Sunday, 07/01/2018 7:00:23 PM

Sunday, July 01, 2018 7:00:23 PM

Post# of 438
EIGR recently announced an expanded licensing deal MRK

MRK is now partnered with EIGR in both their Lonafamib programs. These programs will initiate Ph3 trials before the end of Q1/19.

EIGR is a leader in Hepatitis D, likely to become a disease of greater concern as Central Asian human filth continues to pour into Western Civilization.

EIGR raised cash on 5/18 expanding its runway into 2020.

Also, it would be wise to track the prospect of EIGR receiving a priority review voucher.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up